What is Merck & Co.'s lynparza — liabilities?

Merck & Co. (MRK) reported lynparza — liabilities of $600.00M in Q4 2022.

What does lynparza — liabilities mean?

The total debt and financial obligations directly tied to a specific product line.

Discontinued — last reported Q4 '22

Lynparza — Liabilities

Merck & Co. Lynparza — Liabilities remained flat by 0.0% to $600.00M in Q4 2022 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementSegment

CategoryLeverage

SignalLower is better

VolatilityStable

First reportedQ4 2018

Last reportedQ4 2022

Rolls up toTotal Liabilities

How to read this metric

An increase may signal rising operational costs or new investment in the product, whereas a decrease suggests the settlement of obligations or reduced activity related to the product.

Detailed definition

This metric represents the total outstanding financial obligations specifically attributable to the operations, developm...

Peer comparison

Comparable to segment-specific liability reporting in diversified industrial or pharmaceutical companies that track product-level profitability.

Metric ID: mrk_segment_lynparza_liabilities

Historical Data

2 periods

	Q1 '22	Q4 '22
Value	$600.00M	$600.00M
QoQ Change	—	+0.0%

Range$600.00M – $600.00M

Similar Metrics at Other Companies

Berkshire HathawayBRK.A View metric

BiogenBIIB View metric

DowDOW View metric

S&P GlobalSPGI View metric

Arch Capital GroupACGL View metric

PrologisPLD View metric

Frequently Asked Questions

What is Merck & Co.'s lynparza — liabilities?: Merck & Co. (MRK) reported lynparza — liabilities of $600.00M in Q4 2022.
What does lynparza — liabilities mean?: The total debt and financial obligations directly tied to a specific product line.